EANS-Adhoc: SYGNIS Pharma AG
SYGNIS announces intended changes in the
Supervisory Board
06.09.2012 – 18:09
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information 06.09.2012 SYGNIS announces intended changes in the Supervisory Board Heidelberg, 6 September 2012 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) shall, as already announced on 18 July, 2012, acquire 100% ownership of X-Pol Biotech, S.L., by way of capital increase against contribution in kind and therefore X-Pol Biotech, S.L., will become a 100% subsidiary of SYGNIS Pharma AG. According to the business valuation as of today and subject to a corresponding resolution of the shareholders of SYGNIS Pharma AG, the existing shareholders of X-Pol Biotech, S.L., will hold 77.5% of all shares in SYGNIS Pharma AG after the proposed transaction. By an approving resolution on the Shareholders' Meeting regarding the therefore necessary capital increase against contribution in kind the Shareholders' Meeting will create the fundamental conditions for a significant change of the shareholder structure of SYGNIS Pharma AG. In the event the Shareholders' Meeting approves the planned capital increase of the Company against contribution in kind, the current Members of the Supervisory Board Prof. Dr. Friedrich von Bohlen und Halbach, Prof. Dr. Christof Hettich, Prof. Dr. Werner Hacke, Prof. Dr. Wolfgang Hartwig, Prof. Dr. Andrea Pfeifer and Dr. Wolf-Dieter Starp have notified the Management Board of SYGNIS Pharma AG subsequently to their Supervisory Board Meeting of 6 September, 2012, about their intention to resign from office with effect of the end of the Shareholders' Meeting approving the capital increase against contribution in kind. By intending to resign from office the needed reorientation of SYGNIS Pharma AG shall be supported. Prof. Dr. Friedrich von Bohlen und Halbach as well as Dr. Wolf-Dieter Starp intend to seek for re- election into the Supervisory Board. For further information please contact: |Peter Willinger | |Co-CEO/CFO | |Tel: +49 (0) 6221-454 836 | |Email: willinger@sygnis.de | ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Marc Risch Telefon: +49 (6221) 454 - 737 E-Mail: Marc.Risch@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt language: English